Budapest, Hungary

Csaba Huszár


Average Co-Inventor Count = 17.5

ph-index = 1


Company Filing History:


Years Active: 2001

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Inventor Spotlight: Csaba Huszár from Budapest, Hungary**

Introduction

Csaba Huszár is an innovative inventor based in Budapest, Hungary. His work contributes significantly to the field of chemistry, particularly in the development of compounds that are crucial for pharmaceutical applications. With a total of two patents, Huszár's inventions demonstrate his expertise and commitment to advancing scientific research.

Latest Patents

Huszár's latest patents include a process for the preparation of 1,3-diaza-spiro (4.4) non-1-en-4-one derivatives and 1-cyano-1-acylamino-cyclopentane intermediates. This process involves multiple reactions where a compound of formula (III) is treated with various reagents, producing intermediates that are vital for synthesizing angiotensin II antagonists. The reactions are meticulously designed to operate in a medium with a pH above 7, ensuring the successful transformation of compounds into their desired forms.

Career Highlights

Csaba Huszár is affiliated with Sanofi-Synthelabo, a major player in the pharmaceutical industry. His role in the company allows him to engage in pioneering research and development projects, focusing on innovative solutions within the realm of drug discovery. His contributions are at the forefront of medical advancements, emphasizing the importance of research-based innovation.

Collaborations

Throughout his career, Huszár has collaborated with esteemed colleagues such as Attila Kis-Tamás and Attila Németh. These partnerships have enriched his research, promoting a collaborative environment that facilitates the exchange of ideas and innovative solutions in the field.

Conclusion

In conclusion, Csaba Huszár stands out as a noteworthy inventor in the pharmaceutical sector. His patents reflect his dedication to improving drug synthesis processes, ultimately contributing to the betterment of healthcare through innovative chemistry. As he continues to work at Sanofi-Synthelabo, his ongoing research is likely to lead to further advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…